User:Wehehee/TissueTransplantation

From Wikipedia, the free encyclopedia

Tissue transplantation is a surgical procedure involving the removal of tissue from a donor site or the creation of new tissue, followed by tissue transfer to the recipient site.[1][2] The aim of tissue transplantation is to repair or replace tissues that are missing, damaged, or diseased, thereby improving patients’ survival, functionality and quality of life.[2]

The practice of tissue transplantation dates back to 1600 BC and has undergone vast advancements since then. The four main types of tissue transplantation are xenotransplantation, allotransplantation, isotransplantation and autotransplantation, while the common tissues transplanted include skin, bone, corneal and vessel grafts.[3]

Tissue transplantation comes with risks and complications, including immune rejection and viral infections. Other than concerns about medical risks, medical ethics are also key factors for consideration during tissue transplantation.

Further research in tissue engineering, regenerative medicine, immunosuppressants and gene editing holds the potential to enhance the efficiency and outcome of tissue transplantation.

History[edit]

The Edwin Smith papyrus, containing the earliest surgical records of tissue transplantation.

The earliest record of tissue transplantation can be traced back to the Edwin Smith Papyrus, a surgical document dating back to around 1600 BC. Skin grafting techniques to treat injuries were mentioned in this ancient text.[4][5]

The first officially documented tissue transplant is a skin transplant from 1869, performed by Swiss surgeon Jacques-Louis Reverdin.[6] Reverdin’s technique involved transplanting tiny and thin portions of skin called “epidemic grafts” onto patients’ wounds, which resulted in successful epidermal proliferation.[6] This paved the way for subsequent advancements in skin grafting, such as the first successful skin grafting surgery to treat burns by British surgeon George Davis Pollock in 1870.[7]

Tissue transplantation has undergone drastic advancements since the discovery of adaptive immunity for tissue rejection by Brazilian-British biologist Peter Medawar in the 1950s.[8] This has led to the development of immunosuppressive drugs, such as Azathioprine (Imuran), which has been widely used in tissue transplantation since the 1960s.[9] Together with improvements in transplantation practices, such as tissue typing, success rates of tissue transplantation rose.

Types of Tissue Transplantation[edit]

Xenotransplantation[edit]

Xenotransplantation is a cross-species tissue transplantation from animal to human.[10][11] The development of blood vessel anastomosis opened the door for xenotransplantation during the 20th century, which led to numerous attempts in organ transplantations with tissues from nonhuman primates (NHPs). This is due to the pathobiological barriers between species, including the activation of innate and adaptive immune systems, coagulation dysregulation, inflammation and profound toxicity.[12] As genetic modification technology matures, genetically modified pigs have slowly been made to bridge the genetic incompatibility arising from xenotransplantation. This is achieved by modifying the porcine cell gene to synthesize human complement-regulatory proteins.[13]

Allotransplantation[edit]

Allotransplantation refers to tissue transplant between individuals with different genetic makeup.[10][11] Although the genetic composition variation in allografts is not as large as that in xenografts, the rejection rate remains high. To minimize rejection, cautious donor-recipient matching is needed.[10][14] This includes tissue typing, which is the crossmatching of donor and recipient through matching human leukocyte antigens (HLA) and ABO blood antigens.[10][14] Additional measures like screening donors for any diseases like AIDS, hepatitis B, hepatitis C and syphilis before extracting the tissues are done to further ensure the recipients' safety.[15][16]

Isotransplantation[edit]

Isotransplantation refers to tissue transplants between individuals with the same genetic makeup.[10][11] An example of isotransplantation would be the transplantation of tissues between identical twins, which are twins who share the same genetic composition. This is shown in the first successful living donor kidney transplantation procedure performed by Dr. Joseph E. Murray in 1954 between identical twins.[11][17] Given the unique nature of this type of transplantation, there will be little to no chance of rejection due to the sharing of the same genetic materials. Hence, immunosuppressants would be unnecessary.[10]

Autotransplantation[edit]

Autotransplantation refers to tissue transplantation from one part of the body to another.[10][11] This type of transplantation is usually performed when one part of the body needs the tissue urgently. Hence, similar tissue from another part of the body that is in excess is sourced as the autograft.[10][11] This can be seen in procedures like autologous orthopedic transplant, which remains the “gold standard” of bone grafting methods through extracting grafts from places like the iliac crest and transplanting them to the targeted fracture spot.[18] Since the tissue is transplanted from one part of the body to another part with the same genetic composition, rejection is implausible.[10]

Common Types of Tissues Transplanted[edit]

A skin graft over a wound.
Integra™, a synthetic skin.

Skin grafts[edit]

Skin grafts are used to treat wounds and burns. Autologous full-thickness grafts involving transplantation of the entire epidermis and dermis to provide better cosmetic outcomes can be used for smaller wounds.[19] As for larger wounds, autologous split-thickness grafts involving transplantation of the epidermis and partial portion of the dermis are used.[19] More extensive wounds or burns would typically require allografts sourced from cadavers.[19] Artificial skin can also be used in treating serious burns or chronic skin wounds.[20]

An animation showing the iliac crest (the red areas).

Bone grafts[edit]

Bone grafts repair damaged bones or help heal fractures. Autograft tissues are commonly obtained from the posterior iliac crest due to their high osteogenic potential and ability to supply both cancellous and cortical bones.[21] Autografts are preferred as they possess osteoconductive scaffolds, osteoinductive signaling molecules and osteogenic cells, meaning they provide scaffolds for bone growth, stimulate bone growth and generate bone cells, while allografts only possess osteoconductive properties.[22] Synthetic grafts include the use of substances like hydroxyapatite and calcium phosphate derivatives.[22]

An eye that has undergone penetrating keratoplasty.
An eye that has undergone Boston keratoprosthesis.

Corneal grafts[edit]

Corneal grafts from allografts help restore vision, relieve pain or improve appearance in patients with corneal disease or damage.[23] The three main types of corneal transplantation include penetrating keratoplasty involving transplantation of the whole cornea with a corneal button, lamellar keratoplasty involving replacement of the outer and middle corneal layers, and endothelial keratoplasty involving replacement of the inner layer of the cornea.[23] Artificial corneal transplants, also known as keratoprosthesis, have been getting increasingly advanced and popular over the past decade, with Boston keratoprosthesis and Osteo-odonto-keratoprosthesis being the most commonly performed transplants.[24]

Vascular grafts[edit]

Vascular grafts are used to replace or bypass damaged or occluded vessels. For small-diameter vessels (<6mm), autologous vessels usually involve the harvesting of the saphenous vein or the femoral artery.[25] However, due to the limited vessel availability and the invasiveness of vessel harvesting, cryopreserved vessel allografts from deceased donors are used.[26] Synthetic vascular grafts that are clinically approved include polyurethane, expanded polytetrafluoroethylene and PET (Dacron®).[27]

Other types of tissues transplanted include cartilage, adrenal tissue, bone marrow, heart valve and composite transplantation of facial tissues.

Risk and Complications[edit]

Immune rejection is the main barrier that impedes success achieved via tissue transplantation. It can be categorized into three stages: hyperacute, acute and chronic rejection.[10][11][28] Hyperacute rejection arises within 24 hours after the transplantation, and is characterized by a violent immune reaction that destroys grafts within hours after transplantation.[10][29] Acute rejection arises within the first week to 6 months after transplantation and could be further categorised into acute humoral rejection or acute cellular rejection.[10][29] Chronic rejection is the loss of graft function due to sustained immune response against the graft, leading to the functional loss of tissue graft from months to years.[10][29]

One standard method for treating the complications that arise from immune rejection is using immunosuppressive drugs.[10] However, immunosuppressive drugs also increase the risk of other complications like opportunistic infections, the second barrier for tissue transplantation, due to decreased immunity.[28] Additional side effects like delayed wound healing and toxicity response are also significant issues to address when using most immunosuppressive drugs.[28]

Medical Ethics[edit]

Medical ethics is of huge importance in tissue transplantation and is built upon the four pillars of autonomy, beneficence, non-maleficence and justice.

Autonomy pertains to the rights of both donors and recipients.[30] No matter living or deceased, autonomous consent to tissue extraction should be obtained from the donor, in which the donor should be fully informed, mentally competent and acting voluntarily when providing consent.[31] With tissue shortage, some countries such as France, Italy, Russia and Singapore have adopted the opt-out system, under which all adults are presumed to have consented to tissue donation after death unless opted out.[32] For the recipients, they should also be fully informed about the benefits and risks of the tissue transplantation procedures.

Under the dual principles of beneficence and non-maleficence, tissue transplantation procedures should maximize the benefits while minimizing potential harm to both the donor and recipient.[30] This includes proper assessment of the urgency of tissue transplant and careful matching of the donor and the recipient.

Justice in tissue transplantation involves ensuring equitable access to transplantation for all.[30] Allocation systems which vary between countries are put in place to ensure the ethical distribution of tissues with considerations such as recipients’ medical urgency and waiting time.[33] Comprehensive guidelines are also put in place to ensure the ethical use of biotechnology in tissue transplantation.[33]

Future Directions[edit]

Tissue engineering, like 3D bioprinting, is an emerging field of study about constructing tissue-like structures by precisely layering cells, growth factors and biomaterials.[34] This field could revolutionize tissue transplants by synthesizing personalized grafts for enhanced integration without immune rejection and reducing reliance on donors.[34]

A diagram of stem cell differentiation, showing the potential of stem cells in creating personalised tissues of various body parts for transplantation.

The field of regenerative medicine, specifically stem cell therapy, also holds immense potential for tissue transplantation. The use of human pluripotent stem cells, specifically induced pluripotent stem cells, offers the cultivation of personalized tissues that minimize rejection risks.[35] Moreover, they enable direct tissue repair within the body, potentially sidestepping the need for surgery and reducing infection risks.[35]

Other directions include the advancements in immunosuppressive medication, which aims to reduce the side effects of immunosuppressive drugs, as well as gene editing, which aims to increase the integrability of animal tissues into humans.[36][13]

While the above prospects hold tremendous potential, they are still in preclinical stages, with various obstacles, such as ethical issues and safety, that have yet to be addressed.

References[edit]

  1. ^ Oli, Angus N.; Rowaiye, Adekunle Babajide; Adejumo, Samson Adedeji; Anazodo, Francis Ifeanyi; Ahmad, Rahnuma; Sinha, Susmita; Haque, Mainul; Adnan, Nihad; Oli, Angus N.; Rowaiye, Adekunle B.; Adejumo, Samson Adedeji; Anazodo, Francis I.; Ahmad, Rahnuma; Sinha, Susmita; Haque, Mainul (2022-11-01). "Classic and Current Opinions in Human Organ and Tissue Transplantation". Cureus. 14 (11). doi:10.7759/cureus.30982. ISSN 2168-8184. PMC 9624478. PMID 36337306.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  2. ^ a b "Overview of Transplantation - Immunology; Allergic Disorders". MSD Manual Professional Edition. Retrieved 2024-04-07.
  3. ^ "Key Facts | Overview | Transplant Safety | CDC". www.cdc.gov. 2022-10-13. Retrieved 2024-04-07.
  4. ^ van Middendorp, Joost J.; Sanchez, Gonzalo M.; Burridge, Alwyn L. (2010-08-10). "The Edwin Smith papyrus: a clinical reappraisal of the oldest known document on spinal injuries". European Spine Journal. 19 (11): 1815–1823. doi:10.1007/s00586-010-1523-6. ISSN 0940-6719. PMC 2989268. PMID 20697750.
  5. ^ Kohlhauser, Michael; Luze, Hanna; Nischwitz, Sebastian Philipp; Kamolz, Lars Peter (2021-03-04). "Historical Evolution of Skin Grafting—A Journey through Time". Medicina. 57 (4): 348. doi:10.3390/medicina57040348. ISSN 1648-9144. PMC 8066645. PMID 33916337.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  6. ^ a b Nordham, Kristen D.; Ninokawa, Scott (2022-01-02). "The history of organ transplantation". Baylor University Medical Center Proceedings. 35 (1): 124–128. doi:10.1080/08998280.2021.1985889. ISSN 0899-8280. PMC 8682823. PMID 34970061.{{cite journal}}: CS1 maint: PMC format (link)
  7. ^ Ozhathil, Deepak K.; Tay, Michael W.; Wolf, Steven E.; Branski, Ludwik K. (2021-04-15). "A Narrative Review of the History of Skin Grafting in Burn Care". Medicina. 57 (4): 380. doi:10.3390/medicina57040380. ISSN 1010-660X. PMC 8071142. PMID 33920783.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  8. ^ Simpson, Elizabeth (2015-04-19). "Medawar's legacy to cellular immunology and clinical transplantation: a commentary on Billingham, Brent and Medawar (1956) 'Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance'". Philosophical Transactions of the Royal Society B: Biological Sciences. 370 (1666): 20140382. doi:10.1098/rstb.2014.0382. ISSN 0962-8436. PMC 4360130. PMID 25750245.{{cite journal}}: CS1 maint: PMC format (link)
  9. ^ MUNTEAN, ADRIANA; LUCAN, MIHAI (2013). "Immunosuppression in kidney transplantation". Clujul Medical. 86 (3): 177–180. ISSN 1222-2119. PMC 4462507. PMID 26527942.
  10. ^ a b c d e f g h i j k l m n Oli, Angus N; Babajide Rowaiye, Adekunle; Adejumo, Samson Adedeji; Anazodo, Francis Ifeanyi; Ahmad, Rahnuma; Sinha, Susmita; Haque, Mainul; Adnan, Nihad. "Classic and Current Opinions in Human Organ and Tissue Transplantation". Cureus. 14 (11): e30982. doi:10.7759/cureus.30982. ISSN 2168-8184. PMC 9624478. PMID 36337306.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  11. ^ a b c d e f g Wang, H. (2011-01-01), Moo-Young, Murray (ed.), "5.51 - Organ Transplant: Strategies for Prevention of Antibody-Mediated Allograft Rejection", Comprehensive Biotechnology (Second Edition), Burlington: Academic Press, pp. 669–683, ISBN 978-0-08-088504-9, retrieved 2024-04-08
  12. ^ Cooper, D. K. C.; Gaston, R.; Eckhoff, D.; Ladowski, J.; Yamamoto, T.; Wang, L.; Iwase, H.; Hara, H.; Tector, M.; Tector, A. J. (2018-03-01). "Xenotransplantation-the current status and prospects". British Medical Bulletin. 125 (1): 5–14. doi:10.1093/bmb/ldx043. ISSN 1471-8391. PMC 6487536. PMID 29228112.
  13. ^ a b Lu, Tianyu; Yang, Bochao; Wang, Ruolin; Qin, Chuan (2019). "Xenotransplantation: Current Status in Preclinical Research". Frontiers in Immunology. 10: 3060. doi:10.3389/fimmu.2019.03060. ISSN 1664-3224. PMC 6989439. PMID 32038617.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  14. ^ a b Marino, Jose; Paster, Joshua; Benichou, Gilles (2016). "Allorecognition by T Lymphocytes and Allograft Rejection". Frontiers in Immunology. 7: 582. doi:10.3389/fimmu.2016.00582. ISSN 1664-3224. PMC 5155009. PMID 28018349.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  15. ^ Ju, Sunghun; Lee, Choongwoo; Jung, Jiyoung; Jeong, Jinyoung (2021-11-15). "Transition from Secondary Blood Test to Nucleic Acid Amplification for Safe Allograft Transplantation". Clinics in Orthopedic Surgery. 13 (4): 564–568. doi:10.4055/cios21031. ISSN 2005-4408. PMC 8609207. PMID 34868507.
  16. ^ Eastlund, Ted (2005-01-01), Kennedy, John F.; Phillips, Glyn O.; Williams, Peter A. (eds.), "VIRAL INFECTIONS TRANSMITTED THROUGH TISSUE TRANSPLANTATION", Sterilisation of Tissues Using Ionising Radiations, Woodhead Publishing Series in Biomaterials, Woodhead Publishing, pp. 255–278, ISBN 978-1-85573-838-6, retrieved 2024-04-08
  17. ^ Tilney, Nicholas L. (1986-06-01). "Renal transplantation between identical twins: A review". World Journal of Surgery. 10 (3): 381–388. doi:10.1007/BF01655297. ISSN 0364-2313.
  18. ^ Schmidt, Andrew H. (2021-02-03). "Autologous bone graft: Is it still the gold standard?". Injury. 52 Suppl 2: S18–S22. doi:10.1016/j.injury.2021.01.043. ISSN 1879-0267. PMID 33563416.
  19. ^ a b c Prohaska, Joseph; Cook, Christopher (2024), "Skin Grafting", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30422469, retrieved 2024-04-07
  20. ^ Przekora, Agata (2020-07-06). "A Concise Review on Tissue Engineered Artificial Skin Grafts for Chronic Wound Treatment: Can We Reconstruct Functional Skin Tissue In Vitro?". Cells. 9 (7): 1622. doi:10.3390/cells9071622. ISSN 2073-4409. PMC 7407512. PMID 32640572.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  21. ^ Archunan, Maheswaran W; Petronis, Sandris (2021-09-04). "Bone Grafts in Trauma and Orthopaedics". Cureus. doi:10.7759/cureus.17705. ISSN 2168-8184.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  22. ^ a b Valtanen, Rosa S.; Yang, Yunzhi P.; Gurtner, Geoffrey C.; Maloney, William J.; Lowenberg, David W. (2020-07-19). "Synthetic and Bone tissue engineering graft substitutes: What is the future?". Injury. 52: S72–S77. doi:10.1016/j.injury.2020.07.040.
  23. ^ a b "Cornea transplant". nhs.uk. 2017-10-24. Retrieved 2024-04-07.
  24. ^ Fu, Lanxing; Hollick, Emma J. (2024), "Artificial Cornea Transplantation", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 33760451, retrieved 2024-04-07
  25. ^ Pashneh-Tala, Samand; MacNeil, Sheila; Claeyssens, Frederik (2015-10-07). "The Tissue-Engineered Vascular Graft—Past, Present, and Future". Tissue Engineering Part B: Reviews. 22 (1): 68–100. doi:10.1089/ten.teb.2015.0100. ISSN 1937-3368.
  26. ^ Bossi, Matteo; Tozzi, Matteo; Franchin, Marco; Ferraro, Stefania; Rivolta, Nicola; Ferrario, Massimo; Guttadauro, Chiara; Castelli, Patrizio; Piffaretti, Gabriele (2017). "Cryopreserved Human Allografts for the Reconstruction of Aortic and Peripheral Prosthetic Graft Infection". Annals of Vascular Diseases. 10 (4): 391–397. doi:10.3400/avd.oa.17-00068. PMC 5835436. PMID 29515701.{{cite journal}}: CS1 maint: PMC format (link)
  27. ^ Leal, Bruna B. J.; Wakabayashi, Naohiro; Oyama, Kyohei; Kamiya, Hiroyuki; Braghirolli, Daikelly I.; Pranke, Patricia (2021). "Vascular Tissue Engineering: Polymers and Methodologies for Small Caliber Vascular Grafts". Frontiers in Cardiovascular Medicine. 7. doi:10.3389/fcvm.2020.592361/full. ISSN 2297-055X.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  28. ^ a b c Claeys, Elisa; Vermeire, Kurt (2019-11-12). "Immunosuppressive drugs in organ transplantation to prevent allograft rejection: Mode of action and side effects". Journal of Immunological Sciences. 3 (4).
  29. ^ a b c Cascalho, Marilia; Platt, Jeffrey L. (2008-01-01), Rich, Robert R.; Fleisher, Thomas A.; Shearer, William T.; Schroeder, Harry W. (eds.), "81 - Challenges and potentials of xenotransplantation", Clinical Immunology (Third Edition), Edinburgh: Mosby, pp. 1215–1222, ISBN 978-0-323-04404-2, retrieved 2024-04-08
  30. ^ a b c COTRAU, Petru; HODOSAN, Viviana; VLADU, Adriana; DAINA, Cristian; DAINA, Lucia Georgeta; PANTIS, Carmen (2019-03-25). "Ethical, Socio-Cultural and Religious Issues in Organ Donation". Mædica. 14 (1): 12–14. doi:10.26574/maedica.2019.14.1.12. ISSN 1841-9038. PMC 6511665. PMID 31123506.
  31. ^ Cotrau, Petru; Hodosan, Viviana; Vladu, Adriana; Timar, Călin; Daina, Lucia; Pantis, Carmen; Negrau, Marcel; Daina, Cristian; Vernic, Corina (2019-12-03). "Occupational Stress and Burnout Syndrome among ICU Nurses. A Prospective Observational Study". Central European Annals of Clinical Research. 1 (1): 1. doi:10.35995/ceacr1010003. ISSN 2668-7305.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  32. ^ Shepherd, Lee; O’Carroll, Ronan E.; Ferguson, Eamonn (2014-09-24). "An international comparison of deceased and living organ donation/transplant rates in opt-in and opt-out systems: a panel study". BMC Medicine. 12 (1): 1–14. doi:10.1186/s12916-014-0131-4. ISSN 1741-7015.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  33. ^ a b Sánchez-Ibañez, Jacinto; Humphreys, Christine; Lomero, Mar; Escoto, Manuel; Weiss, Matthew J.; Wilson, Murray; López-Fraga, Marta (2023-04-28). "Tissue and Cell Donation: Recommendations From an International Consensus Forum". Transplantation Direct. 9 (5): e1466. doi:10.1097/TXD.0000000000001466. ISSN 2373-8731. PMID 37138555.
  34. ^ a b Ma, Yue; Deng, Bo; He, Runbang; Huang, Pengyu (2024-01-17). "Advancements of 3D bioprinting in regenerative medicine: Exploring cell sources for organ fabrication". Heliyon. 10 (3): e24593. doi:10.1016/j.heliyon.2024.e24593. ISSN 2405-8440. PMC 10838744. PMID 38318070.{{cite journal}}: CS1 maint: PMC format (link)
  35. ^ a b Piao, Jinghua; Zabierowski, Susan; Dubose, Brittany N.; Hill, Ellen J.; Navare, Monalisa; Claros, Nidia; Rosen, Siera; Ramnarine, Kiran; Horn, Callie; Fredrickson, Craig; Wong, Karen; Safford, Brent; Kriks, Sonja; El Maarouf, Abderrahman; Rutishauser, Urs (2021-02-04). "Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01". Cell Stem Cell. 28 (2): 217–229.e7. doi:10.1016/j.stem.2021.01.004. ISSN 1934-5909. PMC 7903922. PMID 33545080.{{cite journal}}: CS1 maint: PMC format (link)
  36. ^ Gummert, Jan F.; Ikonen, Tuija; Morris, Randall E. (1999-06-01). "Newer Immunosuppressive Drugs: A Review". Journal of the American Society of Nephrology. 10 (6): 1366. doi:10.1681/ASN.V1061366. ISSN 1046-6673.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Wehehee/TissueTransplantation&oldid=1218231374"